

FORM 7

MONTHLY PROGRESS REPORT

Name of CNSX Issuer: Cannabix Technologies Inc. (the "Issuer").

Trading Symbol: BLO

Number of Outstanding Listed Securities: 104,024,104 common shares

Date: for August 5, 2019

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by the CNSX Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the CNSX.ca website.

This report is intended to keep investors and the market informed of the Issuer's ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the CNSX Policies. The discussion in this report must be factual, balanced and non-promotional. *See cautionary note on forward looking statements at the end of this report.

General Instructions

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term "Issuer" includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

The issuer, "Cannabix Technologies Inc.", or "Cannabix", or "the Company" is developing a marijuana breathalyzer for law enforcement and the workplace. Cannabix is advancing its products to enable law enforcement personnel to use this technology to enhance the detection of marijuana in relation to impaired driving offences on North

American roads at a time when marijuana is becoming legal for recreational and medical use in many jurisdictions.

2. Provide a general overview and discussion of the activities of management.

Cannabix Technologies is developing a diversified portfolio of breath testing technologies to detect THC. Cannabix has filed its own patent applications and has licensed the following from the University of Florida:

US Patent 8,237,118 - field of use: exclusive worldwide rights in breath analysis of controlled substances.

PCT/CA2017/000042 - field of use: exclusive worldwide rights in breath analysis of controlled substances.

The Company has entered into research agreements with Dr. Rick Yost at the University of Florida to develop a breath detection device based upon high-field ion mobility and mass spectrometry, known as "FAIMS". The Company is working to identify Tetrahydrocannabinol (THC- the psychoactive component of marijuana that causes intoxication) in ultra low ranges using FAIMS and FAIMS-mass spectrometer systems (FAIMS-MS). The objective of the Company is to develop FAIMS based device that would be used in the field by law enforcement and in the workplace to test for individuals under the influence of marijuana. The Company is actively characterizing its FAIMS device and establishing repeatable results in multiple devices and continuously working to improve resolving power and discrimination of ions. FAIMS works as an "ion blocking" technology, essentially blocking unwanted ions/analytes and allowing specified ions to pass through for detection. The characterization work has been conducted using a bench version of the FAIMS device. Cannabix scientists have been actively tuning the FAIMS device coupled to real time switchable mass spectrometry to detect key molecules and their complex pathways in the body to enable the identification of recency of use. The Company is at the prototype development stage.

During the month the company reported achievement of the highest Δ^9 -tetrahydrocannabinol ("THC") detection levels collected from human breath to date. Over the last several months, Company scientists have studied the unique chemical interactions of THC and cannabinoids in breath, and developed and evaluated novel methods to efficiently and practically capture and ionize THC and cannabinoid analytes collected from several different subjects. These analytes are typically found in extremely low quantities due to their relatively low volatilities, requiring an efficient sampling method. The Company's newly developed methods and technologies for sample capture are an important milestone and represent a significant advancement in the field of human breath studies. These novel capture methods could have implications for both point-of-care and lab-based instruments that would provide real-time results from breath samples, targeting analytes of a wide range of volatilities.

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

There were no new products developed during the month.

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

There were no products or services discontinued during the month.

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

None to report.

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

None to report.

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

None to report.

8. Describe the acquisition of new customers or loss of customers.

The Company does not have customers at the time of this report.

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

During the month the Company provided the following general update regarding the Company's patent portfolio which includes an exclusive worldwide license of University of Florida ("UF") US Patent 8,237,118 in the area of breath analysis of controlled substances using Partial Ovoidal FAIMS Electrode (high field asymmetric waveform ion mobility spectrometry). Additionally, the Company has licensed patent pending technology from UF (US 16/082220) relating to using FAIMS detection, and has filed its own patent applications commencing in 2015.

The Company's technology has significantly progressed since its original filings, and improvements have been made to every aspect of the instrument (in particular related to Company's originally filed US and Canadian patent application Nos. 14/689434 and 2887841). New intellectual property and trade secrets have been developed that will ultimately supersede earlier patent applications. The Company's intellectual property is growing and additional patent applications will be filed in due course. Additional applications that are already pending include Canadian and US applications directed to an intercept system (ignition interlock device) for controlled substances (Nos. 3041860 and 16/344578).

An ignition interlock device requires a driver to blow into an installed device confirming the driver is not impaired before the vehicle will start. Many countries are requiring an ignition interlock device as a condition for drivers convicted of driving under the influence of alcohol and drugs, especially repeat offenders.

The Company routinely receives official correspondence related to its pending patent applications from Canadian and US Patent and Trademark Offices. Such correspondence requires a formal response from the Company to refine the application to address any objections raised by the offices. Such official correspondence can be expected by the Company as it is normal for patents to be initially refused (even a few times) by the patent office. The Company is entitled to submit arguments and/or amend its claims in order to address the Examiner's reasons for rejection to secure grant of a patent. As usual, Company patent lawyers review the merits of the Patent Office's comments and prepare and file responses as required.

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

None to report.

11. Report on any labour disputes and resolutions of those disputes if applicable.

None to report.

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

There were no legal proceedings to which the Issuer became a party during the month.

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

There was no new indebtedness incurred or repaid by the Issuer during the month.

14. Provide details of any securities issued and options or warrants granted.

During the month, the Company issued the following shares in relation to warrant/stock option exercises: nil.

15. Provide details of any loans to or by Related Persons.

There were no new loans to, or by, Related Persons during the month.

16. Provide details of any changes in directors, officers or committee members.

There were no changes in directors, officers or committee members, during the month.

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

Market trends for the Issuer's diversified marijuana breathalyzer technology holdings remain favourable given the ongoing need to detect drugged drivers in North America and globally by law enforcement and the ongoing need in organizations to drug test employees for safety reasons. In addition, there is legalization of marijuana for

recreational use in several U.S. states, with several other states expected to adopt adult use regulations within the next few years. In Canada, legalized recreational use of marijuana became law in fall 2018.

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to CNSX that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all CNSX Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated August 5, 2019_____.

Rav Mlait
Name of Director or Senior Officer
(signed) "Rav Mlait"
Signature

Chief Executive Officer
Official Capacity

Issuer Details Name of Issuer	For Month End	Date of Report YY/MM/DD
Cannabix Technologies Inc.	July 31, 2019	2019/08/05
Issuer Address		
501 - 3292 Production Way		
City/Province/Postal Code	Issuer Fax No.	Issuer Telephone No.
Burnaby, BC, V5A 4R4	604-676- 2767	604-551- 7 83 1
Contact Name	Contact Position	Contact Telephone No.
Rav Mlait	CEO	604-551- 7 83 1
Contact Email Address	Web Site Address	
info@ cannabixtechnologies. com	http://www.cannabixtechnologies.com	

*Cautionary Statement Regarding Forward-Looking Statements

This document contains forward-looking information that involves various risks and uncertainties regarding future events. Such forward-looking information can include without limitation statements based on current expectations involving a number of risks and uncertainties and are not guarantees of future performance of the Company, such as final development of a commercial or prototype product(s), successful trial or pilot of company technologies, no assurance that commercial sales of any kind actually materialize; no assurance the Company will have sufficient funds to complete product development. There are numerous risks and uncertainties that could cause actual results and the Company's plans and objectives to differ materially from those expressed in the forward-looking information, including: (i) adverse market conditions; (ii) risks regarding protection of proprietary technology; (iii) the ability of the Company to complete financings; (v) the ability of the Company to develop and market its future product; and (vi) risks regarding government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition and other factors which may be identified from time to time in the Company's public announcements and filings. There is no assurance that the marijuana breathalyzer business will provide any benefit to the Company, and no assurance that any proposed new products will be built, work successfully or proceed. There is no assurance that existing "patent pending" technologies licensed by the Company will receive patent status by regulatory authorities. The Company is not currently selling commercial breathalyzers. Actual results and future events could differ materially from those anticipated in such information. These and all subsequent written and oral forward-looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Except as required by law, the Company does not intend to update these forward-looking statements.